医学
依托泊苷
肿瘤科
内科学
抗体-药物偶联物
化疗
肺癌
临床试验
抗体
免疫学
单克隆抗体
作者
Mylène Wespiser,R. Gille,M. Pérol
标识
DOI:10.1080/13543784.2025.2512566
摘要
I-DXd is currently being evaluated in the phase III IDeate-Lung02 trial. Its promising efficacy, manageable safety profile, and potential in combination strategies position it as a key candidate for future SCLC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI